Fundraising was primarily intended to enhance OneMap platform's clinical and strategic partnerships.
About One Biosciences
A precision oncology biotech company pioneering clinical-grade single-cell tumour profiling. The OneMap platform transforms clinical samples into high-resolution functional tumour profiles to support personalized therapy selection.
Paris, France
Read Company ProfileFrequently Asked Questions
What type of funding round did One Biosciences raise?
One Biosciences raised a series-a round.
How much did One Biosciences raise in its series-a?
One Biosciences raised $15,000,000 EUR in its series-a.
When did One Biosciences raise its series-a?
One Biosciences raised its series-a on 2025-07-17.
What was One Biosciences's valuation after the series-a?
One Biosciences was valued at $20,000,000 EUR after the series-a.
Who invested in One Biosciences's series-a?
The investors in One Biosciences's series-a are: Redmile Group, Blast, Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, Kima Ventures.
What type of investment was One Biosciences's series-a?
One Biosciences's series-a was a equity investment.
How will One Biosciences use the funds from its series-a?
One Biosciences plans to use the funds for: Accelerate clinical development, Support scaling of strategic partnerships.